{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:12:24Z","timestamp":1788977544668,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>B-cell maturation antigen is a pivotal therapeutic target for multiple myeloma (MM). Membrane-bound BCMA can be cleaved by \u03b3-secretase and shed as soluble BCMA (sBCMA). sBCMA can act as a neutralizing sink to compete with drug, as well as serve as a diagnostic\/prognostic biomarker for MM. Antibody-capture based methods, such as enzyme-linked immunosorbent assay (ELISA) and immunoaffinity-liquid chromatography-multiple reaction monitoring (IA-LC-MRM), have been reported and well adopted to measure sBCMA in clinical samples. However, both methods are biased by capturing antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We have used various LC-MS workflows to characterize and quantify endogenous sBCMA in MM patient samples, including bottom-up peptide mapping, intact analysis, IA-based, and reagent-free (RF)-LC-MRM quantitation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We have confirmed that sBCMA contains a variable N-terminus and a C-terminus that extends to the transmembrane domain, ending at amino acid 61. Leveraging an in-house synthesized G-1-61 sBCMA recombinant standard, we developed a RF-LC-MRM method for unbiased sBCMA quantitation in MM patient samples. By comparing the results from RF-LC-MRM with ELISA and IA-LC-MRM, we demonstrated that RF-LC-MRM measures a more complete pool of endogenous sBCMA compared to the antibody-based methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This work fills the knowledge gap of the exact sequence of endogenous sBCMA for the first time, which differs from the current commercially available standard. Additionally, this work highlights the necessity of identifying the actual sequence of an endogenous soluble target such as sBCMA, both for bioanalytical purposes and to underpin pharmacodynamic measurements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvad145","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:24:09Z","timestamp":1704385449000},"page":"339-349","source":"Crossref","is-referenced-by-count":4,"title":["Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1383-8588","authenticated-orcid":false,"given":"Xiaomeng","family":"Shen","sequence":"first","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Shi","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Protein Sciences, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lan","sequence":"additional","affiliation":[{"name":"Clinical Biomarkers, Amgen Research, Amgen Inc. , Thousand Oaks, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Ching","family":"Lim","sequence":"additional","affiliation":[{"name":"Protein Sciences, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Ang","sequence":"additional","affiliation":[{"name":"Clinical Biomarkers, Amgen Research, Amgen Inc. , Thousand Oaks, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kratzer","sequence":"additional","affiliation":[{"name":"Translational Safety and Bioanalytical Sciences, Amgen Research, Amgen Inc. , M\u00fcnchen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan A","family":"Rock","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke M","family":"Rock","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc. , South San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"2024012006452880600_hvad145-B1","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1002\/ajh.25734","article-title":"Presence of soluble and cell-surface B-cell maturation antigen in systemic light-chain amyloidosis and its modulation by gamma-secretase inhibition","volume":"95","author":"Godara","year":"2020","journal-title":"Am J Hematol"},{"key":"2024012006452880600_hvad145-B2","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2024012006452880600_hvad145-B3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hemato Oncol"},{"key":"2024012006452880600_hvad145-B4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024012006452880600_hvad145-B5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Eng J Med"},{"key":"2024012006452880600_hvad145-B6","first-page":"249","article-title":"FDA Approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2024012006452880600_hvad145-B7","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024012006452880600_hvad145-B8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/17512433.2016.1243055","article-title":"Impact of shed\/soluble targets on the PK\/PD of approved therapeutic monoclonal antibodies","volume":"9","author":"Samineni","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024012006452880600_hvad145-B9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cimb44040098","article-title":"sBCMA plasma level dynamics and anti-BCMA CAR-T-cell treatment in relapsed multiple myeloma","volume":"44","author":"Seipel","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"2024012006452880600_hvad145-B10","doi-asserted-by":"crossref","first-page":"3658215","DOI":"10.1155\/2019\/3658215","article-title":"Soluble markers of antibody secreting cell function as predictors of infection risk in rheumatoid arthritis","volume":"2019","author":"Gutierrez","year":"2019","journal-title":"J Immunol Res"},{"key":"2024012006452880600_hvad145-B11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/bio-2018-0082","article-title":"Development of an ELISA-LC-MS hybrid assay for quantification of biotherapeutics","volume":"10","author":"Chen","year":"2018","journal-title":"Bioanalysis"},{"key":"2024012006452880600_hvad145-B12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/adt.2020.1024","article-title":"A flexible multiplatform bioanalytical strategy for measurement of total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug","volume":"19","author":"Stauffer","year":"2021","journal-title":"Assay Drug Dev Technol"},{"key":"2024012006452880600_hvad145-B13","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1021\/cr3003533","article-title":"Protein analysis by shotgun\/bottom-up proteomics","volume":"113","author":"Zhang","year":"2013","journal-title":"Chem Rev"},{"key":"2024012006452880600_hvad145-B14","doi-asserted-by":"crossref","first-page":"245291","DOI":"10.1155\/2011\/245291","article-title":"Sample preparation techniques for the untargeted LC-MS-based discovery of peptides in complex biological matrices","volume":"2011","author":"Finoulst","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"2024012006452880600_hvad145-B15","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/ac3034757","article-title":"Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry","volume":"85","author":"Jian","year":"2013","journal-title":"Anal Chem"},{"key":"2024012006452880600_hvad145-B16","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1021\/ac500986t","article-title":"Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS\/MS","volume":"86","author":"Torsetnes","year":"2014","journal-title":"Anal Chem"},{"key":"2024012006452880600_hvad145-B17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/ac5033066","article-title":"Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry","volume":"87","author":"Chen","year":"2015","journal-title":"Anal Chem"},{"key":"2024012006452880600_hvad145-B18","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1073\/pnas.1309417110","article-title":"B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention","volume":"110","author":"Huang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012006452880600_hvad145-B19","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1021\/pr400877e","article-title":"Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma","volume":"12","author":"Lin","year":"2013","journal-title":"J Proteome Res"},{"key":"2024012006452880600_hvad145-B20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fchem.2020.00280","article-title":"Cysteines and disulfide bonds as structure-forming units: insights from different domains of life and the potential for characterization by NMR","volume":"8","author":"Wiedemann","year":"2020","journal-title":"Front Chem"},{"key":"2024012006452880600_hvad145-B21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"2024012006452880600_hvad145-B22","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1200\/JCO.2021.39.15_suppl.8047","article-title":"Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and\/or refractory multiple myeloma","volume":"39","author":"Girgis","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024012006452880600_hvad145-B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jim.2010.07.014","article-title":"Pharmacokinetic immunoassay methods in the presence of soluble target","volume":"361","author":"Verch","year":"2010","journal-title":"J Immunol Methods"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/1\/339\/56253466\/hvad145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/1\/339\/56253466\/hvad145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T06:46:20Z","timestamp":1705733180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/70\/1\/339\/7505401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,4]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvad145","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1]]}}}